Introduction {#s1}
============

The dopamine transporter (DAT) is a twelve transmembrane transporter which is recognized as the primary modulator of dopaminergic signaling within the brain ([@B83]). The functional roles of DAT within the dopaminergic system are well characterized *in vitro* and in mature mammalian models and include the regulation and maintenance of dopamine levels ([@B18]; [@B57]; [@B4]; [@B13]; [@B31]; [@B21]). These actions facilitate central nervous system processes such as attention, learning, cognition, motor activity, and mood. Consequently, alterations in dopaminergic transmission and DAT expression stand to adversely affect these neurological activities resulting in behavioral disorders ([@B1]; [@B46]). Dysregulated DAT is associated with neurodevelopmental disorders such as autism spectrum disorder (ASD) and attention deficit hyperactivity disorder (ADHD) ([@B84]; [@B56]; [@B48]; [@B76]). In addition to controlling dopamine levels within the synapse, DAT is the target of both therapeutic and illicit compounds ([@B59]; [@B65]; [@B87]; [@B68]; [@B9]). These compounds carry out their neurobehavioral effects by enhancing, antagonizing or altering DAT expression, which subsequently changes DA signaling ([@B20]; [@B73]). The significant role of DAT in controlling dopaminergic transmission provides the incentive for studies aimed at understanding its regulation.

Although originally thought to have a relatively long half-life ([@B62]), DAT has since demonstrated to have a half-life of about 2 days suggesting a more dynamic process of transcriptional and translational regulation ([@B40]; [@B35]). Several studies have characterized the developmental expression of DAT *in vivo* yet none have explored the mechanisms responsible for the changes in expression levels. Following many cloning and localization studies of DAT ([@B19]; [@B37]; [@B70]; [@B81]), the developmental mRNA expression profiles of the gene were characterized. Using autoradiography and *in situ* hybridization techniques, these studies showed DAT mRNA expression is first detected in early embryonic days and expression levels peak within the first month after birth in rodents ([@B42]; [@B15]; [@B80]; [@B7]; [@B8]; [@B77]; [@B52]; [@B16]). Despite this, the mechanisms involved in DAT developmental regulation remain unclear.

Previously, our lab and others have employed *in vitro* methods to evaluate the molecular mechanisms involved in DAT gene regulation ([@B27]; [@B23]; [@B24]). The dopaminergic transcription factors Nurr1 and Pitx3 are essential for the development, survival and maintenance of midbrain dopaminergic neurons ([@B43]; [@B64]; [@B67]). These transcription factors also demonstrate cooperative binding to the DAT promoter to enhance gene expression ([@B49]). In conjunction with other studies, we and others have shown that histone acetylation and DNA methylation are involved in altered DAT mRNA expression *in vitro* ([@B85]; [@B72]; [@B27]; [@B23]; [@B24]), suggesting the potential for epigenetic mechanisms in DAT gene regulation *in vivo*. Although *in vitro* evidence firmly suggests the role of transcription factors and epigenetic mechanisms in DAT regulation, no studies have explored their contributions during *in vivo* development. In this study we assess DAT mRNA expression during postnatal stages of rat brain development and evaluate the relative contributions of epigenetic modifications and transcription factors to changes in gene expression.

Methods {#s2}
=======

Animals {#s2_1}
-------

Ten-week-old Long-Evans rat breeding pairs were purchased from Charles River Laboratories (Wilmington, MA). Rats were housed according to the American Animal Association Laboratory Animal Care guidelines and bred under standard conditions at Rutgers University School of Public Health. Rats were maintained on a 12:12 light/dark cycle, and food and water were available *ad libitum*. Brains from male offspring were collected at postnatal day (PND) ages: 0, 3, 7, 14, 28, 56, and 182 (approximately 6 months). Midbrain and striatum were immediately frozen in liquid nitrogen and stored at −80°C. The International Animal Care and Use Committee at Rutgers University approved all animal handling procedures.

RNA Isolation and cDNA Synthesis {#s2_2}
--------------------------------

Total RNA was isolated from midbrain tissue using the Qiagen RNeasy Kit (Qiagen, Hilden, Germany) as described previously ([@B29]). RNA concentration was determined using the NanoDrop 2000 spectrophotometer (NanoDrop Technologies, Wilmington, DE) at 260 nm wavelength. One µg of RNA was used for cDNA synthesis with the First Strand Synthesis Kit (Invitrogen, Carlsbad, CA) following the manufacturer instructions.

Real-Time Quantitative Polymerase Chain Reaction {#s2_3}
------------------------------------------------

Rat primer sequences ([Table 1](#T1){ref-type="table"}) were obtained from PubMed. Single amplicon primers were designed using the National Center for Biotechnology Information PrimerBLAST application (<http://www.ncbi.nlm.nih.gov/tools/primer-blast/index.cgi>). A single PCR product of expected amplicon size was confirmed by agarose gel electrophoresis (data not shown). Reactions were prepared in a total volume of 25 µl using SYBR Green Master Mix (Applied Biosystems, Foster City, CA). qPCR was performed using the ViiA7^™^ Real-Time PCR system using the following conditions: 2 min at 50°C and 10 min at 95°C, followed by 40 cycles of 95°C for 15 s and 1 min at the annealing temperature for each primer set. All samples were run in duplicate and analyzed using the 2^−ΔΔCT^ ([@B47]) with TATA binding protein used as a normalizer for each gene.

###### 

Primers used for qPCR ChIP, and pyrosequencing methods. qPCR gene target sequences were obtained from the mRNA nucleotide sequence available on PubMed. Primers were generated in PrimerBLAST each with a product length of 150--200 bp and all span exon-exon junctions. ChIP target gene primers were obtained from a previously published manuscript ([@B27]). Each of the ChIP target primer pairs encompasses 200 bp regions of the DAT promoter. The pyrosequencing primers were purchased from Qiagen.

  Gene Target                    Primer Sequence (5'→3')
  ------------------------------ ---------------------------
  rDAT                           F: GAGGTTTCCCTACCTGTGCT
  R: GTGAAGCCCACACCTTTCAG        
  rDNMT1                         F: GCCCCATGAAACGCTCTAAG
  R: GTGGGTGTTCTCAGGCCTAT        
  rDNMT3a                        F: AAGGCACTCGCTGGGTCAT
  R: AGGACTTCGTAGATGGCTTTGC      
  rDNMT3b                        F: AAATCCAGGGACTTGCAGGAA
  R: GGTCTCTGGTGTACAGACTGG       
  rHDAC1                         F: CAGAAGCCAAAGGGGTCAAA
  R: AAAATCTGAGAAATTGAGGGAAAGT   
  rHDAC2                         F: CTGCAGTTGCCCTTGATTGT
  R: CAGGCGCATGTGGTAACATT        
  rHDAC3                         F: ACTTCGAGTACTTTGCCCCA
  R: GCCTCGTCAGTCCTGTCATA        
  rHDAC5                         F: ATGGCCTTGGATGGGCATTA
  R: CGACTCGTTGGGAGAGTTCA        
  rHDAC8                         F: ATACTTGACCGGGGTCATCC
  R: CCACATGCTTCAGATTCCCTTT      
  rTBP                           F: CACCACCCCCTTGTATCCTT
  R: CAGCAAACCGCTTGGGATTA        
  **ChIP Target**                
  DAT I                          F: TACAGGACCTCAGAGCTGAA
  R: CCCTTAGTTCTGTGTGGAACG       
  DAT II                         F: GCCTCTGGCTCCCCGCAGTC
  R: AGTCCCTCTTCACAGCTCTG        
  DAT III                        F: AACCAGTCGTTGGGAGCCCA
  R: GGGCCGGCGAGGGGCTTGAC        
  DAT IV                         F: CTTGCTTTGTCCCTGCGGAG
  R: GCGAGGTTGTCAGAAGCAGA        
  DAT V                          F: ACCGCACTTGTGACCATAGG
  R: GGACGCACCGCCCGGTGCTG        
  DAT VI                         F: TATAGGTTTCTCCAGGGAAA
  R: AATACGGATCCAGGGGTTGG        
  **Pyrosequencing Target**      **Primer Catalog Number**
  DAT 1                          PM00444052
  DAT 2                          PM00444059
  DAT 3                          PM00444066
  DAT 4                          PM00444073

DNA Bisulfite Conversion and Pyrosequencing {#s2_4}
-------------------------------------------

DNA from frozen midbrain tissues of PND 3, 7 and 56 rats were isolated using DNeasy Blood and Tissue Kit (Qiagen) per manufacturer instructions. DNA concentrations were determined using the NanoDrop2000 spectrophotometer. One µg of DNA was used for bisulfite conversion using EpiTect Bisulfite Conversion Kit (Qiagen) according to the kit instructions. Bisulfite modified DNA was amplified using PyroMark PCR Kit per insert instructions. Briefly, 20 ng of bisulfite converted DNA was mixed with 1x of PyroMark PCR master mix, CoraLoad Concentrate and pre-designed CpG PCR Primer (Qiagen). PCR was performed using the following conditions: 95°C for 15 min, 45 cycles of 94°C for 30 s, 56°C for 30 s, 72°C for 30 s and a single elongation step at 72°C for 10 min. Single amplification products were verified by electrophoresis on a 1% agarose gel. A total of 15 µl of PCR product was used for pyrosequencing using the PyroMark Q24 System (Qiagen). The biotinylated PCR product was bound to streptavidin coated sepharose beads (GE Healthcare, Chicago, IL), washed, and denatured using the PyroMark vacuum prep tool. The single stranded PCR product was released into Advanced Annealing Buffer (Qiagen) containing 1× pre-designed CpG sequencing primer (Qiagen), heated at 80°C for 5 min and processed. The catalog number of primers used in these assays is located in [Table 1](#T1){ref-type="table"}. All assays included non-CpG cytosines to verify efficient bisulfite conversion and were performed in triplicate.

Western Immunoblotting {#s2_5}
----------------------

Frozen striatal tissues were homogenized in buffer (320 mM sucrose, 5 mM HEPES, pH 7.4) containing protease inhibitor cocktail (Sigma-Aldrich) and centrifuged at 3,500 rpm for 5 min at 4°C. Supernatant was transferred to a fresh tube and spun at 14,000 rpm for 45 min at 4°C. Protein pellets were resuspended in buffer and supplemented with 0.1% protease inhibitor cocktail. Homogenate concentrations were determined using the Pierce^™^ bicinchoninic acid (BCA) assay kit (Thermo Scientific) and 20 µg of protein sample was loaded per lane on a 4--12% Bis-Tris Polyacrylamide Gel (Invitrogen). Membranes containing transferred proteins were blocked in milk solution (7.5% milk in 0.1% Tween 20 and Tris buffered saline) for 1 h. Membranes were incubated overnight at 4°C with DAT antibody (1:250; sc-14002 Santa Cruz) followed by 1 h room temperature incubation with anti-rabbit HRP conjugated secondary antibody. Membranes were visualized using Alpha Innotech Fluorochem Imaging System. The membrane was stripped using Pierce Stripping Buffer and re-probed with syntaxin to confirm equal loading.

Chromatin Immunoprecipitation Assay {#s2_6}
-----------------------------------

Frozen midbrain samples were crushed to a fine powder and crosslinked in fixation buffer (1× PBS pH 7.4, 1% formaldehyde and 0.1% protease inhibitor cocktail) for 10 min. The reaction was halted with 10× glycine to a final concentration of 0.125 M for 5 min. Tissue was pelleted at 2,000 rpm for 5 min and washed with cold PBS twice. The pellet was resuspended in cold cell lysis buffer (10 mM Tris pH 8, 10 mM NaCl, 3 mM MgCl~2~, 0.5% NP40) for 15 min. Nuclei were pelleted at 2,000 rpm for 5 min at 4°C and resuspended in nuclear lysis buffer (1% SDS, 5 mM EDTA, 50 mM Tris pH 8). Chromatin was prepared and quantitated as described previously ([@B24]). Briefly, ChIP was performed with 4 µg of each antibody H3K9K14ac (cat \# 9441, Cell Signaling), Nurr1 (cat \# sc-991, Santa Cruz), Pitx3 (cat \# 19307, Santa Cruz), Normal Rabbit IgG (cat\# 12-370, Millipore) overnight at 4°C. Isolated DNA was subjected to qPCR to determine relative enrichment of histone and transcription factor proteins in DAT promoter regions. *Gapdh* levels were measured as a control using the same assay methods and antibodies. Primer sequences for qPCR were obtained from a previously published manuscript ([@B27]) and are found in Table 1. For each ChIP assay, data were normalized to input, IgG and represented as enrichment relative to control.

Statistical Analyses {#s2_7}
--------------------

All data were analyzed and graphs generated using GraphPad Prism 7.0 Software (GraphPad Software, San Diego, CA). All experiments were performed in three or more replicates. Data are presented as mean ± SEM and analyzed by One-way analysis of variance (ANOVA), with the appropriate *post hoc* test indicated in the Results section and figure legends. Statistical significance was determined at level of p ≤ 0.05.

Results {#s3}
=======

Dopamine Transporter mRNA Expression and Protein Levels Peak at Postnatal day 56 in Developing Midbrain {#s3_1}
-------------------------------------------------------------------------------------------------------

Previous studies used autoradiography or semi-quantitative *in situ* hybridization techniques to determine the initial expression, localization, and function of dopamine transporter mRNA and protein in the rat brain ([@B42]; [@B15]; [@B80]; [@B16]). In our study we utilized qPCR, as it provides more accurate quantitation and minimal amounts of RNA, and subsequently cDNA are required compared to *in situ* hybridization techniques ([@B28]). DAT mRNA is concentrated in the neurons of the ventral tegmental area and pars compacta of the substantia nigra, collectively identified as midbrain ([@B71]; [@B3]). We performed qPCR on rat midbrain samples from PND 0 to 6 months of age to determine low, intermediate, and high expression periods for DAT postnatal mRNA expression ([**Figure 1A**](#f1){ref-type="fig"}). Relative DAT mRNA increased two-fold between PND 0 and 3, followed by a 16-fold increase in DAT mRNA by PND 7 which persists until PND 28. DAT mRNA continues to increase until PND 56, when we detect maximum levels of a 51-fold increase and statistical significance has been reached (F~6,14~ = 9.552, p = 0.0003). Immunoblotting of developing rat striatum shows an age-dependent increase in DAT protein levels ([**Figure 1B**](#f1){ref-type="fig"}). One-way ANOVA revealed a significant increase in protein levels of DAT within the striatum at PND 7 and PND 56 relative to PND 3 (F~2,6~ = 177, p \< 0.0001). A 43% increase in DAT protein levels was measured at PND 7 (p = 0.0467), and a 344% increase at PND 56 (p \< 0.0001). Collectively, these data demonstrate a peak at PND 56 for both mRNA and protein in the rat midbrain and striatum respectively.

![Dopamine transporter expression and levels in midbrain and striatum of developing rats. **(A)** DAT mRNA levels in the midbrain were analyzed with qPCR and normalized to TATA binding protein. **(B)** Quantification of DAT protein levels in the striatum were determined by western blot using syntaxin as loading control. Data represented as mean relative to PND 0 (mRNA) or PND 3 (protein) ± SEM; N = 3--4, \*p ≤ 0.05 \*\*\*p ≤ 0.001. Data were analyzed by One-way ANOVA with Dunnett's *post-hoc* with PND 0 as the control for mRNA and PND 3 for protein.](fgene-10-01099-g001){#f1}

Transcriptional Profile of DNA Methylation Enzymes, Histone Deacetylases and Transcription Factors at Postnatal Days 3, 7, and 56 in rat Midbrain {#s3_2}
-------------------------------------------------------------------------------------------------------------------------------------------------

Many studies have evaluated the gene and protein expression profiles of the DAT during development, yet few studies have focused on the mechanisms involved in these changes in expression. DNA methylation is an effective mechanism for silencing gene expression. The addition of methyl groups to the DNA is catalyzed by DNA methyltransferases (DNMTs). We evaluated mRNA expression of three DNMTs in the rat midbrain at PND 3, PND 7 and PND 56. For each DNMT enzyme, we report significant decreases in expression by one-way ANOVA, *Dnmt1* (F~2,9~ = 91.23, p \< 0.0001), *Dnmt3a* (F~2,9~ = 214.6, p \< 0.0001), and *Dnmt3b* (F~2,9~ = 6.915, p \< 0.0001) ([**Figure 2A**](#f2){ref-type="fig"}). *Dnmt1* expression decreased by 17.3% at PND 7 relative to PND 3 (p = 0.0222) and by 71.3% at PND 56 (p \< 0.0001). *Dnmt3a* decreased by 84.3% at PND 56 (p \< 0.0001), and *Dnmt3b* by 30% at PND 7 (not statistically significant) and by 71% at PND 56 (p = 0.0144).

![mRNA expression profiles of epigenetic regulators and transcription factors in the rat midbrain. **(A)** Fold change in DNMT expression relative to control (PND 3). **(B)** Fold change in HDAC expression relative to PND 3. **(C)** Fold change in Nurr1 and Pitx3 expression relative to PND 3. Data represented as fold change in expression ± SEM; N = 3--4, \*p ≤ 0.05, \*\*p ≤ 0.01,\*\*\*p ≤ 0.001. Data were analyzed by One-way ANOVA with Dunnett's *post-hoc* test holding PND 3 as the control.](fgene-10-01099-g002){#f2}

Histone acetylation is another epigenetic modification characterized by the addition of acetyl groups to histone protein tails. These groups are added by histone acetyltransferases and removed by histone deacetylases (HDACs). We focused primarily on HDACs and their mRNA expression in the rat midbrain during PND 3, 7, and 56 ([**Figure 2B**](#f2){ref-type="fig"}). The class I HDACs 1, 2, 3, and 8 expressed differently with age. There was no change in the expression of *Hdac1* and *Hdac3* at PND7, but a significant age-related decrease in *Hdac2* as measured by one-way ANOVA (F~2,9~ = 26.45, p = 0.0002). *Hdac2* mRNA was significantly decreased at PND 7 by 19.5% (p = 0.0342), and by 49% at PND 56 (p \< 0.0001). Conversely, we measured a significant effect of age on *Hdac5* expression (F~2,9~ = 32.29, p \< 0.0001), and *Hdac8* expression (F~2,9~ = 202.2, p \< 0.0001). *Hdac5* expression was increased by 2.12-fold (p \< 0.0001) and *Hdac8* expression was increased by 2.68-fold (p \< 0.001) by PND 56.

The transcription factors Nurr1 and Pitx3 are important regulators of DAT expression ([@B66]; [@B45]) and shown by us and others to regulate DAT at the promoter region ([@B49]; [@B27]; [@B24]). We determined the relative mRNA expression profiles of each transcription factor in the midbrains of PND 3, 7, and 56 rats ([**Figure 2C**](#f2){ref-type="fig"}). Analysis shows no change in Nurr1 gene expression during development. However, *Pitx3* mRNA was significantly increased (F~2,6~ = 94.18, p \< 0.0001). We measured a 7.54-fold (p = 0.0012) increase in expression at PND 7 and an increase of 12.59-fold (p \< 0.0001) by PND 56. These data display an age-related decrease in DNMTs, as well as an increase in *Hdac5*, *Hdac8* and the expression of the Pitx3 transcription factor. Together, these data may support or help explain the mechanism behind the increase in DAT mRNA and protein measured at PND 56.

Pyrosequencing Reveals an Unmethylated DAT Promoter Across all Postnatal Days {#s3_3}
-----------------------------------------------------------------------------

To further assess possible age-related changes in methylation patterns we performed pyrosequencing on the promoter of DAT ([**Figure 3**](#f3){ref-type="fig"}). The epigenetic modification of DNA methylation involves the covalent addition of methyl groups to the C-5 position of cytosine residues at CpG dinucleotide sites ([@B54]) Following bisulfite conversion, we sequenced four promoter regions of the DAT and quantified the relative percent methylation at each CpG site. These data were then averaged across 2--3 rats per group to obtain a mean methylation level for each CpG site. Pyrosequencing results of the four promoter regions show a relatively unmethylated promoter which is consistent across all postnatal days. The approximate regions analyzed *via* pyromark assays are included in the scheme of the promoter in [**Figure 3B**](#f3){ref-type="fig"}. No statistical analysis was performed on these data due to the low number of N's quantified for these measurements.

![Pyrosequencing analysis of DNA methylation in developing rat midbrain. **(A)** Mean methylation level for each CpG site across the four DAT promoter regions examined. Data is represented as mean percent methylation, N = 2--3 and is indicated beside each data point. No statistical analyses were preformed on these data. **(B)** Diagram of the DAT promoter region analyzed in the study. The red arrow indicates the transcription start site (TSS position 0) while the position scale indicates how upstream (negative) or downstream (positive) the primers are in relationship to the TSS. The ChIP targets are presented in boxes with Roman numerals, and the approximate location of the pyrosequencing primers are indicated by arrows. Direction of these arrows indicates whether they target an area on the sense or antisense strand.](fgene-10-01099-g003){#f3}

H3K9/K14 Acetylation Is Increased in Promoter Region 3 at PND 56 {#s3_4}
----------------------------------------------------------------

Acetylation within promoter regions is shown to enhance expression of genes. To determine the direct effects of histone acetylation on DAT gene expression during development, we immunoprecipitated acetylated histone at lysines 9 and 14 (H3K9/K14Ac) to evaluate its enrichment in the DAT promoter. We examined this by probing differences in six regions of the DAT promoter as previously described ([@B27]; [@B24]) ([**Figure 4A**](#f4){ref-type="fig"}). We measured a 100-fold enrichment (to IGG) in the PND 56 group compared to a 30-fold enrichment (to IGG) in the PND 3 group in the third region of the promoter ([**Figure 4B**](#f4){ref-type="fig"}). ANOVA revealed a significant increase in histone acetylation (F~2,5~ = 98.86, p \< 0.0001), with PND 56 having four-fold higher levels of H3K9/K14Ac in region three of the promoter compared to PND 3 (p = 0.0002).

![Chromatin immunoprecipitation of acetylated histone 3 on lysines 9 and 14 (H3K9/K14Ac) within the DAT promoter. **(A)** Enrichment of H3K9/K14Ac across six regions of the DAT promoter normalized to IgG. **(B)** Fold enrichment relative to PND 3 in the third region of the DAT promoter ± SEM; N = 3--4 \*p ≤ 0.05. Data were analyzed by One-way ANOVA with Dunnett's *post-hoc* relative to PND 3 for enrichment.](fgene-10-01099-g004){#f4}

Transcription Factor mRNA and Promoter Binding of Nurr1 and Pitx3 Are Increased at Postnatal day 56 in the rat Midbrain {#s3_5}
-----------------------------------------------------------------------------------------------------------------------

To determine the relative binding of each transcription factor during development, we performed chromatin immunoprecipitation of the DAT promoter with Nurr1 and Pitx3 over 6 regions of the promoter as previously described ([@B27]; [@B24]). There were no changes in Nurr1 or Pitx3 binding between PND 3 and 7 ([**Figures 5A, C**](#f5){ref-type="fig"}). For both proteins, region III of the promoter showed the most abundant enrichment compared to the other regions of the promoter. This is consistent with others showing that enrichment of Nurr1 and Pitx3 in the DAT promoter can cooperatively enhance expression ([@B49]). ANOVA revealed a significant increase in Nurr1 binding (F~2,7~ = 79.47, p \< 0.0001) and in Pitx3 binding (F~2,7~ = 8.13, p = 0.0150) in the third region. These data were graphed to show enrichment relative to PND 3 for both transcription factors. At PND 56 we measured a significant six-fold increase in Nurr1 (p \< 0.0001) and an eight-fold increase in Pitx3 (p = 0.0165) ([**Figures 5B, D**](#f5){ref-type="fig"}).

![Chromatin immunoprecipitation of Nurr1 and Pitx3 within the DAT promoter. **(A)** Enrichment of Nurr1 across six regions of the DAT promoter normalized to IgG. **(B)** Fold enrichment of Nurr1 relative to PND 3 in the third region of the DAT promoter. **(C)** Enrichment of Pitx3 across six regions of the DAT promoter normalized to IgG. **(D)** Fold enrichment of Pitx3 relative to PND 3 in the third region of the DAT promoter. Data for all graphs are presented as ± SEM; N = 3--4 \*p ≤ 0.05 and were analyzed by One-way ANOVA with Dunnett's *post-hoc* relative to PND 3 for enrichment.](fgene-10-01099-g005){#f5}

Discussion {#s4}
==========

The DAT is primarily expressed in the plasma membrane and smooth endoplasmic reticulum of dendrites in the substantia nigra, as well as in the plasma membrane of axons and axon terminals in the striatum of the rat brain ([@B57]). It is responsible for the reuptake of dopamine from the synaptic cleft into the presynaptic terminal and therefore involved in a key mechanism in the termination of dopaminergic signaling. Following reuptake, dopamine can re-enter the neuron where it is recycled into synaptic vesicles ([@B50]). As a key regulator of dopaminergic transmission, the normal expression and proper function of the DAT is essential for maintaining dopamine homeostasis. Aberration in its expression or function is linked to different neurodevelopmental disorders. Understanding the mechanisms involved in the developmental regulation of the DAT may aid in identifying novel avenues to correct the abnormal levels presented in disease states.

We measured the relative expression levels of DAT mRNA during various times of postnatal development. A significant increase in DAT mRNA was observed, and the highest surge was measured by PND 56. Other studies report that PND 56 in the rat corresponds to early human adulthood ([@B69]). Our results differ from previous DAT ontogeny studies, which used *in situ* hybridization and autoradiography techniques. These groups reported maximum expression of DAT at PND 14 ([@B15]), PND 21 ([@B7]) or PND 28 ([@B16]) in contrast to our findings at PND 56. These differences may be explained by older, less sensitive, and less quantitative technologies compared to qPCR. Based on our findings, we selected PND 3, 7, and 56 as low, intermediate, and high expression periods for DAT. These time points were also used in the previous studies. The midbrain dopaminergic neurons project to the striatum where the highest levels of DAT protein are detected. Autoradiography studies using radiolabeled DAT substrates were used to identify regions rich in functional DAT protein ([@B52]; [@B16]). We report significantly higher protein levels of DAT within the striatum at PND 7 and PND 56, with PND 56 showing a maximum for both protein and mRNA levels.

To identify the mechanisms that may be involved in regulating DAT mRNA expression, we explored changes in epigenetic mechanisms in the midbrain. The concept of epigenetics is used to describe both heritable and non-heritable changes in the genome without an alteration to the DNA sequence ([@B17]). These mechanisms are involved in regulating gene expression throughout the lifespan, including but not limited to periods of development, tissue differentiation, and in disease ([@B44]; [@B32]). Of these mechanisms, DNA methylation describes the addition of a methyl chemical group by DNA methyl transferases (DNMTs) to 5-C of cytosines located next to a guanine nucleotide, collectively termed CpG dinucleotide sequences ([@B51]). The addition of methyl groups to the promoter region of a gene increases the methylation of that promoter and is generally associated with transcriptional silencing ([@B51]; [@B12]). During development, DNA methylation serves to epigenetically program genes and alter expression resulting in defined cell identity ([@B61]; [@B79]; [@B82]). Post-translational histone modifications work in tandem with DNA methylation to regulate gene expression and chromatin structure. Histone acetylation is largely associated with relaxed chromatin structure and active gene transcription ([@B26]). Histone deacetylases (HDACs) catalyze the removal of acetyl groups from histone tails, which results in the loosening of higher order chromatin and allowing the gene region of interest to become accessible for transcription ([@B11]). As we have previously reported in our *in vitro* studies, DNMTs as well as HDACs are involved in the regulation and modulation of DAT expression, therefore we sought to investigate their involvement in the *in vivo* regulation of DAT ([@B23]; [@B24]).

We evaluated the expression of DNMTs (*Dnmt1, Dnmt3a, Dnmt3b*) and class I HDACs (*Hdac1, Hdac2, Hdac3, and Hdac8*) and the class IIa HDAC, *Hdac5* genes in the rat midbrain. We show an age-related decrease in mRNA expression for all three genes examined by PND 56 relative to PND 3. This is consistent with others' findings demonstrating that DNMT expression typically diminishes in expression following terminal differentiation and maturation of neurons ([@B22]; [@B10]; [@B14]). We evaluated the expression of HDAC mRNA during PND 3, 7, and 56 of rat brain development. HDAC classes are characterized based on a combination of structural differences and location within the cell ([@B55]). We chose to evaluate all class I HDACs as they are abundantly expressed in the brain. Furthermore, these HDACs are critically important for development as displayed by lethality in HDAC knockout models during embryonic development or during early postnatal days ([@B41]; [@B2]; [@B53]; [@B55]), with the exception of a knockout model of HDAC8 which displays cranial defects, but is otherwise viable ([@B25]). We report no change in expression between *Hdac1* and *Hdac3*, but a decrease in *Hdac2* mRNA by 20% at PND 7 and by 50% at PND 56 relative to PND 3. Conversely, *Hdac8* demonstrated a significant increase in mRNA expression at PND 56. The Class IIa HDAC5 is highly expressed in the brain, and unlike the class I HDACs the knockout models are viable ([@B63]). The major behavioral phenotype of this animal model is enhanced cocaine sensitivity, which suggests a relationship between HDAC5 and the dopaminergic system ([@B63]). In our studies, we observed an increase in *Hdac5* expression. These data suggest that epigenetic factors may play a role in the ontogenic regulation of DAT.

The dopaminergic transcription factors Nurr1 and Pitx3 are expressed early in midbrain dopaminergic cell differentiation ([@B75]; [@B74]). Their mRNA expression persists within the midbrain throughout life and is essential for proper differentiation and maturation of terminal midbrain dopaminergic neurons. DAT is a target gene of Nurr1 and Pitx3 ([@B66]; [@B30]), therefore the two play a major role in the transcriptional regulation of DAT expression. Mice deficient in Pitx3 have significantly decreased levels of DAT ([@B30]), as well as the inability to develop dopaminergic neurons in the substantia nigra ([@B58]; [@B39]). Similarly, mice deficient in Nurr1 also lack midbrain dopaminergic neurons ([@B33]), and deletion of Nurr1 from mature dopaminergic adult neurons increases dopaminergic cell loss, with the neurons of the substantia nigra being more susceptible ([@B34]). We examined expression profiles of both Nurr1 and Pitx3 in the rat midbrain and found that Pitx3 mRNA is significantly increased at both PND 7 and PND 56 of these animals. Collectively, these expression profiles suggest that some of these decreases in DNMTs and HDACs, and the increase of transcriptions factors may be participating in the increased expression of DAT, as they decrease at the same timepoint as we measure maximum DAT expression. These data are consistent with our previous findings *in vitro*, which have shown that increases in mRNA of Nurr1 and Pitx3 are also accompanied by an increase in DAT mRNA ([@B24]).

The actions of these epigenetic factors on directly affecting DAT mRNA expression and ultimately protein levels need to be examined at the promoter level. While evaluating changes in gene expression profiles within the midbrain are valuable and provide us with information about the levels of these epigenetic enzymes, they limit the conclusions drawn about the direct epigenetic modifications and transcription factor binding that occurs on the DAT promoter. *In silico* analyses demonstrated potential epigenetic regulation of DAT due to CpG-rich regions within the promoter ([@B72]). These studies suggested that the lack of a conserved TATA box within the DAT promoter also allows the potential for gene regulation by histone acetylation ([@B5]). DNA methylation is generally associated with transcriptional silencing. Our pyrosequencing results show an unmethylated DAT promoter across all postnatal days. This promoter region was selected for analysis because of its proximity to the *in vitro* tested binding regions of the dopaminergic transcription factors Nurr1 and Pitx3 ([@B49]; [@B86]). Previous studies indicate reduced affinity of transcription factors to their promoter binding sites due to cytosine methylation ([@B78]; [@B38]; [@B60]; [@B6]). Direct alterations in DAT acetylation were determined by ChIP of the DAT promoter with an acetylated histone mark (H3K9/K14Ac), in order to examine regions of the promoter that may be sites of active transcription ([@B36]). Our data indicate significant enrichment of H3K9/K14Ac at PND 56 in the third region of the DAT promoter. Both Nurr1 and Pitx3 demonstrated significant binding and enrichment with the same region of the DAT promoter. An unmethylated promoter and increased histone acetylation within the DAT promoter could make transcription factor binding more accessible, resulting in induced DAT expression. Together, these epigenetic modifications along with transcription factor binding may increase DAT mRNA by directly acting on the promoter region.

These data collectively point to epigenetic mechanisms and transcription factors regulating the ontogenic expression of DAT. We report age-dependent differences in DAT gene expression in the developing rat midbrain. Different expression levels of epigenetic modifier genes suggest a diverse role of these genes during midbrain development. Direct assessments of the DAT promoter confirmed previous findings of transcription factor binding. This solidifies the role of Nurr1 and Pitx3 not only in development, but also in adulthood (PND 56). Age-related reductions in DAT promoter methylation correspond to increased gene expression. In the rat midbrain, the regulation of DAT includes the dopaminergic transcription factors Nurr1, Pitx3 and histone acetylation events. In concert these data contribute to a better understanding of mechanisms by which the DAT gene is regulated during development. As DAT is one of the primary modulators of dopamine levels, this understanding may assist in the therapeutic targeting of molecular components, which contribute to the etiology of neurodevelopmental disorders involving dopaminergic dysregulation.
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